arzoxifene
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Breast Cancer
Conditions
Breast Cancer, Endometrial Cancer, Ovarian Cancer
Trial Timeline
Jan 1, 2001 → Apr 1, 2007
NCT ID
NCT00190697About arzoxifene
arzoxifene is a approved stage product being developed by Eli Lilly for Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00190697. Target conditions include Breast Cancer, Endometrial Cancer, Ovarian Cancer.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00190697 | Approved | Completed |
Competing Products
20 competing products in Breast Cancer